Bristol-Myers Squibb Company (BMY) Stock Profile & Financial OverviewBristol-Myers Squibb Company
BMY Company Overview & Business Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Key Information
Current Trend for BMY
An assessment of the current trend environment for BMY, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for BMY is a Strong Momentum Environment (High Conviction Uptrend).
Daily and weekly trends are in bullish alignment, forming a strong medium-term uptrend.
- The weekly backdrop provides strong tailwinds, confirming that the medium-term path of least resistance is upward.
- Price is currently trending at a healthy distance, sitting 1.86 ATR away from the adaptive KAMA baseline.
- The market is maintaining a healthy 'Higher-High, Higher-Low' sequence, confirming buyer control.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, BMY in a strong expansion phase; Long-term trend is bullish.
Trend Strength: BMY last closed at 54.71, trading 1.4 ATR above the adaptive KAMA baseline (53.02). Technical Classification: Confirmed High-Momentum Uptrend.
Trend Score: Technical Score: 95/100. Classification: Strong/Established. Alignment: High. Logic: Full multi-timeframe alignment with strong momentum filters.
SuperTrend Risk: Structural Support: Adaptive SuperTrend at 48.46. This level serves as the calculated invalidation point for the current upward structure.
Risk Skew: Multi-timeframe risk skew is currently assessed as Constructive Upside. Daily and weekly trends are in high-quality alignment with healthy momentum. Risk skew favors continued upside follow-through from current levels.
Key Levels: In this bullish structure, key support is anchored by immediate support (KAMA) at 53.02, with the critical trend-guard (SuperTrend) at 48.46.